RCS - Arecor Therapeutics - ARECOR ANNOUNCES PRESENTATION AT EASD 2022

Arecor TherapeuticsAnnouncement

04/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220704:nRSD1198Ra&default-theme=true

RNS Number : 1198R  Arecor Therapeutics PLC  04 July 2022

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR ANNOUNCES PRESENTATION AT EASD 2022 OF

PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN
FOR DIABETES

 

Cambridge, UK, 4 July 2022: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that its abstract titled "Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500" has been selected for presentation as part of the Short Oral Discussion Session A at the 58(th) Annual Meeting of the European Association for the Study of Diabetes (
EASD (https://www.easd.org/annual-meeting/easd-2022.html)
) meeting, which will be held from 19-23 September 2022 in Stockholm, Sweden and online.

 

The presentation will take place on Tuesday 20 September during the SO 19 Short Oral Discussion Session "How complicated is type 1 diabetes?" (11:45-12:45)
 

Oral Presentation:          Phase I study investigating PK and PD of
highly-concentrated insulin aspart AT278 U500

Presenting Author:         Dr Eva Svehlikova

Presentation Number:   407

Date and Time:                 Tuesday, 20 September 2022,
between 11:45 and 12:45 (Central European Time)

 

AT278 is an ultra-concentrated (500U/mL) novel formulation of insulin that has
been designed to significantly accelerate insulin absorption post injection to
enable more effective and convenient management of blood glucose levels in
people with high daily insulin requirements.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "AT278 has the
potential to be the first, and potentially only, ultra-concentrated (500U/mL)
yet ultra-rapid acting insulin. This product offers the potential to
significantly improve post prandial control whilst also reducing the injection
volume and number of daily injections for the growing population of people
living with diabetes who have high daily insulin needs, particularly those
with type 2 diabetes. In addition, with its unique profile, AT278 is a key
enabler in the development of next generation miniaturised insulin delivery
devices, an expected future disrupter in the market. We look forward to
sharing our ground-breaking data for this next generation insulin candidate
with scientific colleagues in Stockholm and around the world."

 

 

About the EASD

The European Association for the Study of Diabetes (EASD) is a non-profit,
medical scientific association, founded in 1965 to encourage and support
research in the field of diabetes, the rapid diffusion of acquired knowledge
and to facilitate its application. EASD holds its Annual Meeting in a
different European city each year with more than 15,000 delegates from over
130 countries attending. The scientific programme includes more than 1,200
talks and presentations on the latest results in diabetes research by leading
experts in the field

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray         Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

About AT278

AT278 is Arecor's ultra-concentrated, ultra-rapid acting insulin designed to
accelerate the absorption of insulin post injection, to enable more effective
management of blood glucose levels to the increasing number of people with
diabetes with high daily insulin requirements (>200 units/day), whilst
maintaining the convenience and compliance benefits of being able to deliver
these high insulin doses in a lower injection volume via a single injection.
A truly rapid acting concentrated insulin is a critical step towards the
advancement and miniaturisation of the next generation of insulin delivery
devices.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABKNBKCBKDOOK